One of the approaches to remedy human immunodeficiency virus (HIV) is the use of therapeutic vaccination. We have launched the Provir/Latitude 45 research to determine conserved CTL epitopes in archived HIV-1 DNA based on the HLA class I alleles in aviremic patients under antiretroviral therapy (ART). A HIV-1 polypeptidic therapeutic vaccine based mostly on viral sequence information obtained from circulating blood was proposed; right here, our goal was to check the proviral DNA in blood and gut-associated lymphoid tissue (GALT). Peripheral blood mononuclear cells and intestine biopsies have been obtained from two HIV-1 contaminated patients under profitable antiretroviral therapy.
Total DNA was extracted together with the proviral DNA. The HIV-1 reverse transcriptase was sequenced in each compartments utilizing subsequent era sequencing adopted by single genome sequencing; phylogenetic bushes have been established and in contrast. The proviral sequences of each compartments intra-patient exhibited a really low genetic divergence whereas it was attainable to distinguish the sequences inter-patients; single genome sequencing analysis of two {couples} of samples confirmed that there was no compartmentalization of the sequences intra-patient. We conclude that, contemplating these two instances, the proviral DNA sequences in blood and GALT are comparable and that the epitope analysis of HIV-1 provirus in blood ought to be thought-about as related to that noticed in the GALT, a hard-to-reach main compartment, and can due to this fact be used for therapeutic vaccine approaches.
HIV-1 escapes by buying mutations that differentially affect the course of an infection. Unlike HIV-1 structural and enzymatic proteins, it stays elusive what extent the host immune-mediated choice strain influences the variability of the accent (Vif, Vpu, Vpr, and Nef) and regulatory (Tat and Rev) proteins. To deal with this, we analysed the viral sequences encoding accent and regulatory proteins from 446 HLA-typed, chronically HIV-1 subtype B-infected, and remedy naïve people in Japan. We noticed that Vpu and Vpr have been probably the most and least polymorphic proteins with the common Shannon entropy scores of 0.63 and 0.38, respectively. Phylogenetically corrected strategies recognized a complete of 161 HLA-associated polymorphisms; whereby Nef and Vpu had the best (26.6%) and lowest (1.2%) proportion of amino acid websites related to HLA-class I alleles, respectively.
Prevalence and 1-year incidence of HIV-associated neurocognitive dysfunction (HAND) in adults aged ≥50 years attending normal HIV scientific care in Kilimanjaro, Tanzania
HIV-associated neurocognitive issues (HANDs) are prevalent in older individuals residing with HIV (PLWH) worldwide. HAND prevalence and incidence research of the newly emergent inhabitants of mixture antiretroviral therapy (cART)-treated older PLWH in sub-Saharan Africa are at the moment missing. We aimed to estimate HAND prevalence and incidence utilizing sturdy measures in steady, cART-treated older adults under long-term follow-up in Tanzania and report cognitive comorbidities. A scientific pattern of consenting HIV-positive adults aged ≥50 years attending routine scientific care at an HIV Care and Treatment Centre throughout March-May 2016 and adopted up March-May 2017.
HAND by consensus panel Frascati standards based mostly on detailed domestically normed low-literacy neuropsychological battery, structured neuropsychiatric scientific evaluation, and collateral historical past. Demographic and etiological components by self-report and scientific data. HAND seem extremely prevalent in older PLWH in this setting, the place demographic profile differs markedly to high-income cohorts, and comorbidities are frequent. Incidence and reversibility additionally seem excessive. Future research ought to concentrate on etiologies and doubtlessly reversible components in this setting. These outcomes add additional perception on the position of HLA-mediated choice strain on HIV-1 sequence polymorphisms of HIV-1 accent and regulatory proteins.
Per-protocol analysis of the ZINC trial for HIV illness amongst alcohol customers
The Zinc for INflammation and Chronic illness in HIV (ZINC) trial randomized one who reside with HIV (PLWH) who interact in heavy consuming to both each day zinc supplementation or placebo. The major consequence was change in the Veterans Aging Cohort Study (VACS) index, a predictor of mortality, between baseline and 18 months. Because adherence and follow-up have been suboptimal, the intention-to-treat analysis, which was not statistically vital, might have underestimated the impact of the zinc supplementation. We estimated the per-protocol impact of zinc versus placebo in the ZINC trial (i.e., the impact that will have been noticed if all individuals had had excessive adherence and none was misplaced to follow-up).
 HIV-1 Protease Protein |
|
20-abx263019 |
Abbexa |
-
EUR 328.00
-
EUR 7023.00
-
EUR 230.00
|
|
|
|
 Purified Azide Free) Anti-HIV protease (HIV-1/HIV-2) Purified Azide Free |
|
10-302-C025 |
ExBio |
0.025 mg |
EUR 104 |
Anti-HIV protease (HIV-1/HIV-2) Purified Azide Free |
|
10-302-C100 |
ExBio |
0.1 mg |
EUR 167 |
 HIV protease Antibody |
|
abx140183-01mg |
Abbexa |
0.1 mg |
EUR 370 |
|
|
HIV protease Antibody |
|
abx140378-01mg |
Abbexa |
0.1 mg |
EUR 356 |
|
|
 HIV Protease Substrate IV |
|
H-1048.0001 |
Bachem |
1.0mg |
EUR 113 |
|
Description: Sum Formula: C49H83N15O13; CAS# [128340-47-6] |
HIV Protease Substrate IV |
|
H-1048.0005 |
Bachem |
5.0mg |
EUR 321 |
|
Description: Sum Formula: C49H83N15O13; CAS# [128340-47-6] |
HIV Protease Substrate IV |
|
H-1048.0025 |
Bachem |
25.0mg |
EUR 1169 |
|
Description: Sum Formula: C49H83N15O13; CAS# [128340-47-6] |
 HIV Protease Substrate VI |
|
H-1148.0001 |
Bachem |
1.0mg |
EUR 357 |
|
Description: Sum Formula: C40H66N12O11; CAS# [130877-92-8] |
HIV Protease Substrate VI |
|
H-1148.0005 |
Bachem |
5.0mg |
EUR 1336 |
|
Description: Sum Formula: C40H66N12O11; CAS# [130877-92-8] |
 HIV Protease Substrate VII |
|
H-1286.0001 |
Bachem |
1.0mg |
EUR 357 |
|
Description: Sum Formula: C52H81N15O14; CAS# [128340-45-4] |
HIV Protease Substrate VII |
|
H-1286.0005 |
Bachem |
5.0mg |
EUR 1336 |
|
Description: Sum Formula: C52H81N15O14; CAS# [128340-45-4] |
 Anthranilyl-HIV Protease Substrate |
|
H-2992.0001 |
Bachem |
1.0mg |
EUR 139 |
|
Description: Sum Formula: C43H65N13O11; CAS# [133233-38-2] net |
Anthranilyl-HIV Protease Substrate |
|
H-2992.0005 |
Bachem |
5.0mg |
EUR 466 |
|
Description: Sum Formula: C43H65N13O11; CAS# [133233-38-2] net |
 HIV Protease Substrate III |
|
H-9035.0001 |
Bachem |
1.0mg |
EUR 176 |
|
Description: Sum Formula: C58H95N19O16; CAS# [138608-20-5] |
HIV Protease Substrate III |
|
H-9035.0005 |
Bachem |
5.0mg |
EUR 611 |
|
Description: Sum Formula: C58H95N19O16; CAS# [138608-20-5] |
HIV Protease Substrate III |
|
H-9035.0025 |
Bachem |
25.0mg |
EUR 2352 |
|
Description: Sum Formula: C58H95N19O16; CAS# [138608-20-5] |
 Recombinant HIV-2 Protease Protein, Untagged, E.coli-10ug |
|
QP12271-10ug |
EnQuireBio |
10ug |
EUR 201 |
 Recombinant HIV-2 Protease Protein, Untagged, E.coli-1mg |
|
QP12271-1mg |
EnQuireBio |
1mg |
EUR 5251 |
 Recombinant HIV-2 Protease Protein, Untagged, E.coli-2ug |
|
QP12271-2ug |
EnQuireBio |
2ug |
EUR 155 |
) Active HIV-2 Protease Recombinant (GST-tagged) |
|
7851-100 |
Biovision |
|
EUR 789 |
Active HIV-2 Protease Recombinant (GST-tagged) |
|
7851-20 |
Biovision |
|
EUR 272 |
) HIV-2 Protease Activity Assay Kit (Fluorometric) |
|
K845-100 |
Biovision |
|
EUR 588 |
) HIV protease Antibody (Azide free) |
|
abx140182-01mg |
Abbexa |
0.1 mg |
EUR 370 |
|
|
 Anthranilyl-HIV Protease Substrate III |
|
H-1044.0001 |
Bachem |
1.0mg |
EUR 515 |
|
Description: Sum Formula: C65H100N20O17; CAS# [138668-80-1] net |
Anthranilyl-HIV Protease Substrate III |
|
H-1044.0005 |
Bachem |
5.0mg |
EUR 1965 |
|
Description: Sum Formula: C65H100N20O17; CAS# [138668-80-1] net |
 Anthranilyl-HIV Protease Substrate V |
|
H-1168.0001 |
Bachem |
1.0mg |
EUR 515 |
|
Description: Sum Formula: C50H76N14O13; CAS# [210644-48-7] net |
Anthranilyl-HIV Protease Substrate V |
|
H-1168.0005 |
Bachem |
5.0mg |
EUR 1965 |
|
Description: Sum Formula: C50H76N14O13; CAS# [210644-48-7] net |
 protease Peptide Protein) Immunodeficiency virus (HIV-1) protease Peptide Protein |
|
20-abx169013 |
Abbexa |
-
EUR 328.00
-
EUR 6703.00
-
EUR 913.00
|
|
|
|
 Rabbit Anti HIV-1 gp120 protein IgG, clone 2 |
|
AB-21010-2 |
Alpha Diagnostics |
100 ul |
EUR 469 |
 Recombinant HIV-1 Protease Protein, Untagged, E.coli-10ug |
|
QP12260-10ug |
EnQuireBio |
10ug |
EUR 201 |
 Recombinant HIV-1 Protease Protein, Untagged, E.coli-1mg |
|
QP12260-1mg |
EnQuireBio |
1mg |
EUR 5251 |
 Recombinant HIV-1 Protease Protein, Untagged, E.coli-2ug |
|
QP12260-2ug |
EnQuireBio |
2ug |
EUR 155 |
 HIV-2 Envelope Protein |
|
20-abx260147 |
Abbexa |
-
EUR 885.00
-
EUR 342.00
-
EUR 1372.00
|
|
|
|
 HIV-2 gp32 Protein |
|
20-abx260282 |
Abbexa |
-
EUR 885.00
-
EUR 342.00
-
EUR 1609.00
|
|
|
|
 HIV 2 Envelope Protein |
|
abx060590-1mg |
Abbexa |
1 mg |
EUR 1574 |
|
|
 HIV-2, gp36 Protein |
|
abx061537-1mg |
Abbexa |
1 mg |
EUR 968 |
|
|
HIV-2, gp36 Protein |
|
abx069859-1mg |
Abbexa |
1 mg |
EUR 1094 |
|
|
) HIV-1 Protease Activity Assay Kit (Fluorometric) |
|
K825-100 |
Biovision |
|
EUR 566 |
) HIV-1 Protease Inhibitor Screening Kit (Fluorometric) |
|
K826-100 |
Biovision |
|
EUR 626 |
) HIV Protease Substrate III-B (Native Sequence) |
|
H-9650.0001 |
Bachem |
1.0mg |
EUR 113 |
|
Description: Sum Formula: C51H90N18O14S; CAS# [179912-80-2] |
HIV Protease Substrate III-B (Native Sequence) |
|
H-9650.0005 |
Bachem |
5.0mg |
EUR 321 |
|
Description: Sum Formula: C51H90N18O14S; CAS# [179912-80-2] |
HIV Protease Substrate III-B (Native Sequence) |
|
H-9650.0025 |
Bachem |
25.0mg |
EUR 1169 |
|
Description: Sum Formula: C51H90N18O14S; CAS# [179912-80-2] |
 Rev-A3R5-GFP/Luc HIV Reporter Cells |
|
HRC-2 |
101Bio |
- |
Ask for price |
 HIV-2 gp36 |
|
E62H003 |
EnoGene |
100ug |
EUR 382 |
 HIV-2 Peptide |
|
H-8338.0500 |
Bachem |
0.5mg |
EUR 254 |
|
Description: Sum Formula: C93H140N30O28S2; CAS# [172486-63-4] net |
HIV-2 Peptide |
|
H-8338.1000 |
Bachem |
1.0mg |
EUR 400 |
|
Description: Sum Formula: C93H140N30O28S2; CAS# [172486-63-4] net |
 HIV-1 Envelope conjugated to HIV-2 gp39 Protein |
|
20-abx260144 |
Abbexa |
-
EUR 885.00
-
EUR 342.00
-
EUR 1372.00
|
|
|
|
 Synthetic HIV-2 gp36 Protein |
|
20-abx260067 |
Abbexa |
-
EUR 523.00
-
EUR 258.00
-
EUR 773.00
|
|
|
|
 HIV 2 Envelope gp36 Protein |
|
abx060591-1mg |
Abbexa |
1 mg |
EUR 1358 |
|
|
HIV 2 Envelope gp36 Protein |
|
abx060592-100ug |
Abbexa |
100 ug |
EUR 1066 |
|
|
 HIV-2 gp36 seq Protein |
|
abx060593-1mg |
Abbexa |
1 mg |
EUR 356 |
|
|
 Recombinant HIV-2 gp36 Protein |
|
VAng-0539Lsx-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: HIV type 2 gp36 Antigen, recombinant protein from Pichia pastoris. 1.30 mg/mL. |
) rec HIV-1 Protease (expressed in E. coli) |
|
H-9040.0050 |
Bachem |
50.0µg |
EUR 876 |
rec HIV-1 Protease (expressed in E. coli) |
|
H-9040.0100 |
Bachem |
0.1mg |
EUR 1469 |
rec HIV-1 Protease (expressed in E. coli) |
|
H-9040.0500 |
Bachem |
0.5mg |
EUR 5771 |
 (MW: 1145.3)) HIV-1, HIV-2 Protease Substrate (AA:Ala-Thr-Leu-Asn-Phe-Pro-Ile-Ser-Pro-Trp) (MW: 1145.3) |
|
SP-101043-5 |
Alpha Diagnostics |
5 mg |
EUR 286 |
 HIV-2 gp36 397 a.a Protein |
|
20-abx260283 |
Abbexa |
-
EUR 885.00
-
EUR 342.00
-
EUR 1609.00
|
|
|
|
 HIV-2 gp32, Biotin Labeled Protein |
|
20-abx260364 |
Abbexa |
-
EUR 1247.00
-
EUR 467.00
-
EUR 1970.00
|
|
|
|
 Recombinant HIV-2 gp36 Protein [His] |
|
VAng-0528Lsx-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: HIV type 2 gp36 Antigen, recombinant protein from E. coli, MW 20.775 Da, 1.74 mg/mL. |
 Recombinant HIV-2 Envelope |
|
7-07746 |
CHI Scientific |
1000µg |
Ask for price |
 HIV-2 gp39 Antibody |
|
20-abx137104 |
Abbexa |
|
|
|
|
HIV-2 gp39 Antibody |
|
20-abx137197 |
Abbexa |
-
EUR 1609.00
-
EUR 342.00
-
EUR 1010.00
|
|
|
|
 HIV-2 gp36 Antibody |
|
abx021891-100ug |
Abbexa |
100 ug |
EUR 732 |
|
|
 HIV-RT protein |
|
30-AH80 |
Fitzgerald |
25 ug |
EUR 461 |
|
Description: Purified recombinant HIV-RT protein |
 HIV 1 Protein |
|
abx060583-1mg |
Abbexa |
1 mg |
EUR 1358 |
|
|
 HIV Chimeric Protein |
|
abx061422-1mg |
Abbexa |
1 mg |
EUR 704 |
|
|
HIV Chimeric Protein |
|
abx061423-1mg |
Abbexa |
1 mg |
EUR 704 |
|
|
HIV Chimeric Protein |
|
abx061425-1mg |
Abbexa |
1 mg |
EUR 704 |
|
|
HIV Chimeric Protein |
|
abx061426-1mg |
Abbexa |
1 mg |
EUR 704 |
|
|
 Recombinant HIV-1 Envelope conjugated to HIV-2 gp39 |
|
7-07711 |
CHI Scientific |
100µg |
Ask for price |
Recombinant HIV-1 Envelope conjugated to HIV-2 gp39 |
|
7-07712 |
CHI Scientific |
500µg |
Ask for price |
Recombinant HIV-1 Envelope conjugated to HIV-2 gp39 |
|
7-07713 |
CHI Scientific |
1000µg |
Ask for price |
 (expressed in E. coli)) rec HIV-1 Protease (affinity purified) (expressed in E. coli) |
|
H-1256.0100 |
Bachem |
0.1mg |
EUR 4153 |
rec HIV-1 Protease (affinity purified) (expressed in E. coli) |
|
H-1256.0500 |
Bachem |
0.5mg |
EUR 16521 |
) Lethal factor Protease Substrate 2, pNA derivative MEk2 peptide substrate for high-throughput screening of LF inhibitors (14aa) |
|
LFPS-2 |
Alpha Diagnostics |
1 mg |
EUR 408 |
 HIV-2 gp32, Horseradish Peroxidase Labled Protein |
|
20-abx260365 |
Abbexa |
-
EUR 1247.00
-
EUR 467.00
-
EUR 1970.00
|
|
|
|
 HIV-2 gp36 recombinant antigen |
|
9003 |
Virostat |
100 ug |
EUR 403.44 |
|
Description: This is HIV-2 gp36 recombinant antigen for ELISA,WB. |
HIV-2 gp36 recombinant antigen |
|
8911 |
Virostat |
100 ug |
EUR 561.13 |
|
Description: This is HIV-2 gp36 recombinant antigen for ELISA,WB. |
HIV-2 gp36 recombinant antigen |
|
8949 |
Virostat |
100 ug |
EUR 441.5 |
|
Description: This is HIV-2 gp36 recombinant antigen for ELISA,WB. |
 HIV 1 / 2 p24 Antibody |
|
abx021866-1mg |
Abbexa |
1 mg |
EUR 1010 |
|
|
HIV 1 / 2 p24 Antibody |
|
abx021890-1mg |
Abbexa |
1 mg |
EUR 1010 |
|
|
 HIV-2 gp32 recombinant antigen |
|
00173-V-01mg |
Virogen |
0,1 mg |
EUR 267.5 |
|
|
|
Description: HIV-2 gp32 recombinant antigen. . |
HIV-2 gp32 recombinant antigen |
|
00173-V-1000ug |
Virogen |
1000 ug |
EUR 1282.5 |
|
|
|
Description: HIV-2 gp32 recombinant antigen. . |
 HIV 2 gp36 envelope antigen |
|
00180-V-01mg |
Virogen |
0,1 mg |
EUR 267.5 |
|
|
|
Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36. |
HIV 2 gp36 envelope antigen |
|
00180-V-1000ug |
Virogen |
1000 ug |
EUR 1282.5 |
|
|
|
Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36. |
 anti-HIV-2 gp36 IgG1 |
|
0114-A-01mg |
Virogen |
0,1 mg |
EUR 267.5 |
|
|
|
Description: anti-HIV-2 gp36 IgG1 (monoclonal) Produced against a recombinant protein. |
anti-HIV-2 gp36 IgG1 |
|
0114-A-1000ug |
Virogen |
1000 ug |
EUR 1282.5 |
|
|
|
Description: anti-HIV-2 gp36 IgG1 (monoclonal) Produced against a recombinant protein. |
 BMP-2 Bone Morphogenetic Protein-2 Human Recombinant Protein, Monomer |
|
PROTP12643-2 |
BosterBio |
Regular: 20ug |
EUR 317 |
|
Description: Bone Morphogenetic Protein-2 Human Recombinant produced in E.Coli is a monomeric, non-glycosylated, Polypeptide chain containing 115 amino acids (283-396) and having a molecular mass of 13009 Dalton. ;The BMP-2 is purified by proprietary chromatographic techniques. |
 Protein) Human Protease, Serine 2 (PRSS2) Protein |
|
20-abx166813 |
Abbexa |
-
EUR 676.00
-
EUR 272.00
-
EUR 2068.00
-
EUR 801.00
-
EUR 481.00
|
-
100 ug
-
10 ug
-
1 mg
-
200 ug
-
50 ug
|
|
|
 Protein) Mouse Protease, Serine 2 (PRSS2) Protein |
|
20-abx068710 |
Abbexa |
-
EUR 662.00
-
EUR 272.00
-
EUR 2026.00
-
EUR 787.00
-
EUR 481.00
|
-
100 ug
-
10 ug
-
1 mg
-
200 ug
-
50 ug
|
|
|
 HIV-1 Envelope conjugated to HIV-2 gp39) Recombinant (E.Coli) HIV-1 Envelope conjugated to HIV-2 gp39 |
|
RP-564 |
Alpha Diagnostics |
100 ug |
EUR 286 |
 HIV Protease Protein (9-aa, His-tag, ~12 kda, <95%)) Recombinant (E. coli) HIV Protease Protein (9-aa, His-tag, ~12 kda, <95%) |
|
RP-1633 |
Alpha Diagnostics |
5 ug |
EUR 469 |
 HIV-1 gp41 Protein |
|
20-abx260275 |
Abbexa |
-
EUR 885.00
-
EUR 342.00
-
EUR 1609.00
|
|
|
|
 HIV-1 nef Protein |
|
20-abx260280 |
Abbexa |
-
EUR 885.00
-
EUR 342.00
-
EUR 1609.00
|
|
|
|
 HIV-1 p24 Protein |
|
20-abx261886 |
Abbexa |
-
EUR 4490.00
-
EUR 328.00
-
EUR 230.00
|
|
|
|
HIV-1 p24 Protein |
|
abx169032-1mg |
Abbexa |
1 mg |
EUR 551 |
|
|
 HIV Integrase p31 Protein |
|
abx060581-100ug |
Abbexa |
100 ug |
EUR 732 |
|
|
 HIV 1 gp160 Protein |
|
abx060587-1mg |
Abbexa |
1 mg |
EUR 940 |
|
|
HIV-1 nef Protein |
|
abx060588-05mg |
Abbexa |
0.5 mg |
EUR 940 |
|
|
 HIV 1 p24 Protein |
|
abx060589-1mg |
Abbexa |
1 mg |
EUR 1288 |
|
|
 HIV-1 Ag, Protein |
|
abx061403-1mg |
Abbexa |
1 mg |
EUR 1358 |
|
|
HIV-1 p24 Protein |
|
abx061424-05mg |
Abbexa |
0.5 mg |
EUR 739 |
|
|
 HIV-1, gp41 Protein |
|
abx061536-1mg |
Abbexa |
1 mg |
EUR 968 |
|
|
 HIV-1, p24 Protein |
|
abx069857-1mg |
Abbexa |
1 mg |
EUR 1574 |
|
|
 Recombinant HIV-O Protein |
|
VAng-Lsx0235-inquire |
Creative Biolabs |
inquire |
Ask for price |
|
Description: HIV type O Antigen, Recombinant antigen. |
 Recombinant Human TFF-2 Protein |
|
PROTQ03403-2 |
BosterBio |
20ug |
EUR 317 |
|
Description: The Trefoil Factor peptides (TFF1, TFF2 and TFF3) are expressed in the gastrointestinal tract, and appear to play an important role in intestinal mucosal defense and repair. TFF2 has been shown to inhibit gastrointestinal motility and gastric acid secretion. Recent data suggests a potential role for TFF2 in acute and chronic asthma (Nikolaidis, N.M. et al. Am. Journal Respir. Cell Mol. Biol. (2003) 4: 458-464). Recombinant human TFF2 is a 12.0 kDa polypeptide of 107 amino acid residues, which includes a 40-amino acid trefoil motif containing three conserved intramolecular disulfide bonds. |
 Recombinant Human Relaxin-2 Protein |
|
PROTP04090-2 |
BosterBio |
25ug |
EUR 317 |
|
Description: Relaxin-2 is a peptide hormone structurally related to insulin, which is expressed in the placenta, decidua, prostate, and in the ovary during pregnancy. Of the three known relaxin genes, Relaxin-2 is the only relaxin known to circulate in the blood. Relaxin-2 binds specifically to the LGR7 and LGR8 receptors, previously identified as an “orphan” G protein coupled receptors. Signaling by Relaxin-2 through its target receptors enhances the growth of pubic ligaments and ripening of the cervix during birth. Recombinant Relaxin-2 is a nonglycosylated 6.0 kDa disulfide linked heterodimeric protein consisting of a 24 amino acid A-chain and a 29 amino acid B-chain. |
 Recombinant Murine IL-2 Protein |
|
PROTP04351-2 |
BosterBio |
20ug |
EUR 317 |
|
Description: IL-2 is a powerful immunoregulatory lymphokine produced by T-cells in response to antigenic or mitogenic stimulation. IL-2/IL-2R signaling is required for T-cell proliferation and other fundamental functions which are essential for the immune response. IL-2 stimulates growth and differentiation of B-cells, NK cells, lymphokine activated killer cells, monocytes, macrophages and oligodendrocytes. Recombinant murine IL-2 is a 17.2 kDa protein, containing 149 amino acid residues. |
 Recombinant Human PAI-2 Protein |
|
PROTP05120-2 |
BosterBio |
10ug |
EUR 317 |
|
Description: PAI-2 is an inhibitory serpin expressed mainly in keratinocytes, activated monocytes, and placental trophoblasts. It exists predominantly as a 47 kDa nonglycosylated intracellular protein which can be induced to be secreted as 60 kDa glycoprotein. The glycosylated and unglycosylated forms of PAI-2 are equally effective as inhibitors of urokinase-type plasminogen activator (uPA), the only established physiological target of this serpin. PAI-2 has a unique ability to form dormant polymers spontaneously and reversibly under physiological conditions. The physiological relevance of this property, which is neither a consequence of any mutation in the PAI-2 gene nor associated with any known disorder, is still unclear. However, it appears that the formation of intracellular dormant polymers may be important for the controlled release of the inhibitor from PAI-2 producing cells. Plasma levels of PAI-2 are usually low or undetectable, except during pregnancy and in some forms of monocytic leukemia. Secretion of PAI-2 from the placenta normally occurs during the third trimester of pregnancy and accounts for the dramatic increase in PAI-2 levels (up to 250 ng/ml), which are maintained at these levels until postpartum, and then rapidly decline. In addition to its vital role in protecting the placenta from degradation by uPA and/or uPA-activated proteases, PAI-2 has been shown to be essential for the prevention of metastatic spread of neck, lung and breast cancers. The beneficial effect of PAI-2 seen in these studies is presumed to stem from its ability to inhibit uPA-dependent cell dissemination. PAI-2 has also been reported to inhibit keratinocyte proliferation, and to participate in the innate immune response during viral infection. Recombinant human PAI-2 is a 415-residue nonglycosylated protein. |
 Recombinant Human MMP-2 Protein |
|
PROTP08253-2 |
BosterBio |
10ug |
EUR 317 |
|
Description: Matrix metalloproteinases (MMPs) are a family of endoproteases that require zinc and calcium for expressing catalytic activity. These enzymes play a central role in the maintenance and remodeling of the extracellular matrix. Elevated expression of their activity, caused either by up-regulation of their expression or down-regulation of their cognate inhibitors, has been implicated in various degenerative disorders, including arthritis, cardiovascular disease, skeletal growth-plate disorders, and cancer metastasis. MMP-2 is a secreted collagenase with specificity toward Type IV, V, VII, and X collagens. Recombinant human MMP-2 is a 62.0 kDa protein containing the entire catalytic N-terminal domain and the C-terminal domain (552 amino acids). |
Adherence was measured because the self-reported proportion of tablets taken in the earlier 6 weeks and assessed in any respect post-baseline visits. We used inverse chance weighting to estimate and evaluate the change in the VACS index at 18 months in the zinc and placebo teams, had all of the trial individuals had excessive adherence (i.e., cumulative adherence ≥80% at 18 months). To study traits by stage of adherence, we rerun the analyses utilizing thresholds for prime adherence of 70% and 90% of common self-reported tablet protection. The imply distinction in the change between people in the zinc and placebo teams was – 4.07 (- 11.5, 2.75) and -12.34 (- 20.14, -4.14) for prime adherence outlined as 70% and 90% of tablet protection, respectively. Overall, excessive adherence to zinc was related to a decrease VACS rating, however confidence intervals have been vast and crossed 0. Further research with a bigger pattern dimension are wanted to quantify the advantages of zinc supplementation in this inhabitants.
 HIV-2 gp32)
 HIV-2 gp36)
 HIV-2 Envelope)
)